Printer Friendly

Human T-lymphotropic virus type II among Guaymi Indians - Panama.

Human T-lymphotropic virus type 2 (HTLV-II) is one of four retroviruses (i.e., HTLV-I, human immunodeficiency virus type 1 [HIV-1], and HIV-2] that are known to infect humans. During 1988, investigators from the Gorgas Memorial Laboratory (GML) and the National Institutes of Health (NIH) tested serum specimens collected during 1978--1987 throughout Panama to determine the prevalence of HTLV-I infection (1), which is endemic in southern Japan and the Caribbean basin (2). HTLV seropositivity rates were low in all areas of Panama except among the Guaymi Indians in Changuinola (9%), (*) a city in western Panama (Figure 1). During 1989--1991, additional testing of 36 seropositive specimens from Guaymi Indians detected that the infections were due to HTLV-II (3,4). This report summarizes risk factor data for HTLV-II infection among Guaymi Indians.

During December 1989--March 1990, Guaymi households were randomly selected and contacted for a cross-sectional study to determine risk factors for HTLV-II infection. Serum was collected from 254 persons aged [unkeyable] 1 year for whom consent was obtained, and risk data (i.e., sexual behavior and history of injection) were collected from participants aged [unkeyable] 7 years.

The median age of participants was 16 years (range: 1--72 years); 140 (55%) were male. Although none of 59 participants aged <7 years tested HTLV-antibody--positive, 17 (9%) of 195 persons aged [unkeyable] 7 years tested HTLV-I/II-antibody--positive; all were confirmed by additional testing to be infected with HTLV-II.

Seropositivity rates increased with age and were highest (15%) for those aged >30 years. Although no other association reached statistical significance, infected persons were more likely to report a history of one or more marriages (odds ratio [OR]=3.2; p=0.1), cohabitation with one or more partners (OR=2.1; p=0.3), one or more lifetime sex partners (OR=2.1; p=0.2). HTLV-II infection was not associated with histories of blood transfusion, vaccination, injection, or tattoo.

Reported by: F Gracia, MD, L Castillo, MD, B Armien, MD, Gorgas Memorial Laboratory, Panama. RM Giusti, MD, PH Levine, MD, WA Blattner, MD, National Cancer Institute Bethesda, Maryland. Retrovirus Diseases Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Deseases, CDC.

Editorial Note: HTLV-II has primarily been associated with injecting-drug users (IDUs) and their sex partners (5). In the United States, the initiation of volunteer blood-donor screening for HTLV infection in November 1988 resulted in the identification of approximately 2000 seropositive units of blood donated each year. Of these, at least half were infected with HTLV-II (6).

The Guaymi in Changuinola, who have migrated from traditional living areas in the mountains of western Panama, are the first nondrug-injecting population known to have high rates of HTLV-II infection. Association of HTLV-II infection with other Native American Indian groups have been reported but not confirmed by population-based studies (7).

HTLV-I and HTLV-II are closely related (60% genomic homolgy) and, like the immunodeficiency viruses, have a tropism predominantly for CD4 lymphocytes and infect the human host for life. Serologic tests for HTLV-I, including enzyme immuno-assay, Western blot, and radioimmunoprecipitation assay, also detect HTLV-II through cross-reactivity. Therefore, seropositive results are properly referred to as HTLV-positive or HTLV-I/II--positive, and not as HTLV-I--positive as is sometimes reported. Further discrimination between HTLV-I and HTLV-II requires additional testing with techniques such as polymerase chain reaction or newly developed HTLV type-specific peptide serologic assays. HTLV serologic tests do not cross-react with HIV.

Notification and counseling of infected persons has been difficult because of the lack of information concerning disease risk and transmission. HTLV-II has not been linked with disease. However, because as many as 5% of persons infected with HTLV-I have developed adult T-cell leukemia/lymphoma or HTLV-I--associated myelopathy/ tropical spastic paraparesis (8), there is concern about possible disease associations with HTLV-II infection.

Similarly, the modes of transmission of HTLV-II are not well documented. Both HTLV-I and HTLV-II are highly cell associated, and transmission of either virus is thought to require passage of infected lymphocytes, rather than cell-free body fluids. Within areas endemic for HTLV-I, breastfeeding, sex, and transfusion of infected cellular blood products have transmitted HTLV-I (8).

Preliminary findings among the Guaymi suggest that there may be important differences between HTLV-I and HTLV-II transmission; for example, despite the universal practice of breastfeeding among the Guaymi, lack of seropositivity among young Guaymi children suggests that HTLV-II may not be efficiently passed by this route. In contrast, preliminary data suggest that sexual contact may be the most important route of transmission in this population.

To resolve these issues and to obtain data that may be difficult to acquire from other populations, investigators from the GML, the NIH, and CDC began pilot studies during November 1991 in preparation for a three-part study of HTLV-II infection among Guaymi Indians. Phase I, in which approximately 5000 persons are expected to be enrolled, is a cross-sectional serosurvey of all Guaymi in Changuinola aged [is greater than or equal to] 1 year. In phase II, persons identified as infected with HTLV-II in phase I will be compared with seronegative controls to assess differences in risk behaviors, diseases, and laboratory-measured immunologic parameters possibly associated with HTLV-II. Phase III will be a hospital-based study to identify possible disease associations; HTLV-II infection rates among Guaymi patients will be compared with rates in the general Guaymi population.

References

[1] Reeves WC, Levine PH, Cuevas M. Quiroz E, Maloney E. Saxinger WC Seroepidemiology of human T cell lymphotropic virus in the Republic of Panama. Am J Trop Med Hyg 1990;42: 374-9.

[2] Blattner WA. Retroviruses. In: Evans AS, ed. Viral infections of humans: epidemiology and control. 3rd ed. New York: Plenum, 1989.

[3] Lairmore MD, Jacobson S, Gracia F, et al. Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians of Panama, Proc Natl Acas Sci USA 1990;87:8840-4.

[4] Heneine W, Kaplan JE. Graci F, Lal R, Roberts B. Reeves W. WTHLV-II endemicity among Guaymi Indians in Panama. N Engl J Med 1991;324:565.

[5] Kwok S, Gallo D, Hanson C, McKinney N. Poiesz B. Sninsky JJ. High prevalence of HTLV-ll among intravenous drug abusers: PCR confirmation and typing. AIDS Res Hum Retroviruses 1990;6:561-5.

[6] CDC. Human T-lymphotropic virus type I screening in voluntee blood donors-United States, 1989. MMWR 1990;39:915,921-24.

[7] Hjelle B, Mills R, Swenson S, Mertz G, Key C, Allen S. Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-ll--endemic population. J Infect Dis 1991;163:435--450.

[8] Kaplan JE, Khabbaz RF.HTLV-I: newest addition to blood donor screening. Am Fam Physician 1989;40:189--95.

Availability of Computerized Health Information Database

from World Health Organization, European Region

As part of the international objectives for health for all by the year 2000 (HFA) (1,2), the World Health Organization, European Region (WHO-Europe) developed 38 specific regional HFA targets for that region (3). To monitor progress toward this strategy, WHO-Europe has developed several health-related statistical and textual databases that provide information from the 32 European member states.

The databases are being further developed and adapted with member states to make them more relevant to their users. They allow rapid retrievel of information by each regional objectives, as well as by keywords and subject area. The following databases are currently available: Statistical--Health for All Indicator Database, Food and Health Indicator Databasel, and AIDS Surveillance Database; Textual--Health Legislation Database and Documentation Retrieval Database. All can be accessed through on-line telecommunications.

Additional information is available from WHO Regional Office for Europe, 8 Scherfigsvej, DK-2100 Copenhagen, Denmark; telephone 45 39 17 17 17; telex 15 348 who dk; fax 45 31 18 11 20.

References

[1] WHO. Alma-Ata 1978: primary health care. Geneva: WHO, 1978. (Health for All series no. 1).

[2] WHO. Global strategy for Health for All by the year 2000. Geneva: WHO, 1981. (Health for All series no. 3).

[3] WHO. Targets for Health for All. Copenhagen: WHO Office for Europe, 1985.
COPYRIGHT 1992 U.S. Government Printing Office
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Morbidity and Mortality Weekly Report
Date:Mar 27, 1992
Words:1316
Previous Article:Attitudes of parents of high school students about AIDS, drug, and sex education in schools - Rome, Italy, 1991.
Next Article:Firearm-related deaths - Louisiana and Texas, 1970-1990.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters